Differentiation therapy for IDH1/2 mutant malignancies

Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells.

http://www.nature.com/cr/journal/vaop/ncurrent/full/cr201373a.html